Thank you for letting us get to know mjn-neuro better. Salvador Gutiérrez is part of the management team and a partner of mjn-neuro. He currently holds the position of CFO (chief financial officer), a very important part in the management of the company.

What led you to join mjn-neuro?
My eldest daughter, now 17 years old, attended school in the first grades with a girl one year older, Marina. As you know, Marina has drug-resistant epilepsy. Because of those coincidences that sometimes happen, Marina and Maria became friends. And from that friendship was born the relationship between our family and Marina’s family. I think this is my first contact with epilepsy and little by little we got to know, through Marina, all the difficulties that the disease entails. A few years later, David (Marina’s father) was already determined to start a project to develop a support system for his daughter and so many other people and families who have epilepsy. And he thought that both Xavi (an engineer like David and a former colleague) and I (with experience in the business sector) could help him move forward with the idea. I think that was in 2012. As you can imagine, both Xavi and I said yes to joining mjn-neuro‘s project.

When was mjn-neuro created and what was the driving force behind the development of this project?
mjn-neuro as such is created in 2014. But it is in 2012 when the 3 founders start laying the foundation of what we would like mjn-neuro to be in the future. Anyway, David had already been thinking for some years about how he could help his daughter cope a little better with her epilepsy. He bought a portable encephalography machine, recorded and logged all of Marina’s seizures so he could report that information to her neurologist. In short, he was learning day by day how to best manage Marina’s disease.

What do you think was key to mjn-neuro’s success?
I think the key to mjn-neuro‘s evolution is David’s deep knowledge of what it means to have epilepsy, all the implications it has, all the sacrifices that have to be made at the family level… Or as it still is today, epilepsy is stigmatized by society and unfortunately we have to fight to have equal treatment and opportunities. This, together with his great experience in the management of engineering projects, has made it possible for us to overcome all the obstacles that have been presented to us. I sincerely believe that a project like mjn-neuro is not possible without its origin in a personal problem.

Did you know about epilepsy or do you have someone close to you who has it?
No, the truth is that I only knew the most typical notions of epilepsy and had no one close to me with the disease until I met Marina. I remember perfectly the day I became aware that epileptic seizures are unpredictable. Several years ago, we were having dinner at home and Marina and her sister were playing with my children upstairs. At one point there was a bang and a scream and Marina had fallen and hit her head on the floor after a seizure. My youngest son was pale and was repeating: Thank goodness she didn’t hit the edge of the step! At that moment I realized that having unpredictable epileptic seizures can have fatal consequences at any time. And that the fear and uncertainty that is generated causes the quality of life of these people (and their families) to suffer greatly.

It is in 2012 when the 3 founders started laying the foundation of what we would like mjn-neuro to be in the future.

How do you deal with the stigma of epilepsy in society?
At mjn-neuro we are very aware of this problem. David has taught to the entire team the importance of being a social project. Not only can we improve the quality of life for people with epilepsy thanks to our solution. We also have to work actively to improve society’s understanding of epilepsy, help improve the social inclusion of those affected and gradually decrease the stigma associated with epilepsy.

What are the main functions of your position?
The mjn-neuro team has grown over the past few months. This has allowed me to focus more on the tasks that I have always developed professionally. At present, I am focused on following up on the project’s accounting, analyzing the fulfillment and justification of the different grants that have been awarded to us, or planning the capacity to fulfill our payment and/or tax obligations. Like many other start-ups, we have no recurring income and have to finance ourselves through grants or private capital. This means that we have to foresee our payment capacity several months in advance.

As CFO you have to make different strategic investment or funding decisions, what has been the biggest challenge?
I believe the biggest challenge has been to obtain the necessary resources to make our solution to help people with epilepsy a reality that can help thousands of families as of this year. But this challenge has been shared. The entire mjn-neuro team has worked to be worthy of obtaining the necessary resources.

The search for funding has led you to win different prizes. What is the prize you are most proud of?
I don’t have any preference about the awards we have been given. All of them have been a great injection of motivation to keep going. At first, the prizes we got were more modest, around Girona or Barcelona. But some years ago, and with the evolution of our project, we have achieved awards at a Spanish, European and even world level. And all of them represent a pride for the mjn-neuro team.

Finally, give us some advice, what are two metrics that a CFO should always monitor?

I find it very difficult to give advice… Personally I think that the main metric that you should always keep in mind is the cash flow, or in other words, the ability to pay the staff, suppliers, services… That they consider that your project, throughout all these years, offers confidence in that sense I think it is a very outstanding value.

Thank you very much for your time. Congratulations on all the recognition you have received over the years. Great success for mjn-neuro!

Leave a Reply

The user who fills in the information requested in this form declares to be entitled to do so and is solely responsible for the accuracy and completeness of the data and information entered, expressly exonerating MJN NEUROSERVEIS of any liability that may arise for this entity on the occasion of the information provided through this form.

Yes, I accept

L’usuari que complimenta la informació requerida al present formulari declara estar legitimat per això i es fa responsable exclusiu de la veracitat i integritat de les dades i informació que introdueix, exonerant expressament a MJN NEUROSERVEIS de qualsevol responsabilitat que es pugi generar per aquesta entitat amb ocasió de la informació facilitat a través del present formulari.

Si, accepto

El usuario que cumplimenta la información requerida en el presente formulario declara estar legitimado para ello y se hace responsable exclusivo de la veracidad e integridad de los datos e información que introduce, exonerando expresamente a MJN NEUROSERVEIS de cualquier responsabilidad que pudiera generarse para esta entidad con ocasión de la información facilitada a través del presente formulario.

Sí, acepto

Save the date

The next Saturday 21st of November at 4 pm, you will be able to know first hand our product: mjn-SERAS.
mjn-SERAS is a healthcare product that sends a warning signal when the risk of epileptic seizures is high, to the affected person and their trusted contacts.

Sign up now!

    mjn-SERAS is a medical device with CE marking according to the European Directive 93/42/EEC and the Royal Decree RD. 1591/2009.
    Contraindications: Do not use the product if you suffer from an infection in the ear canal or if you suffer from a skin lesion in the vicinity of the product's area of influence.
    Considerations: This medical product works with an APP only on Android phones. The results tested are 96% sensitivity and 94% specificity.

    Save the date

    El próximo sábado 21 de noviembre a las 4 de la tarde, podrás conocer de primera mano nuestro producto: mjn-SERAS.
    mjn-SERAS es un producto sanitario que lanza una señal de aviso cuando el riesgo de crisis de epilepsia es elevado, a la persona afectada y a sus contactos de confianza.


      mjn-SERAS es un producto sanitario con marcado CE conforme a la Directiva Europea 93/42/EEC y el Real Decreto RD. 1591/2009.
      Contraindicaciones: No usar el producto en caso de padecer una infección en el canal auditivo o en caso de padecer una lesión cutánea en las proximidades del área de influencia del producto.
      Consideraciones: Este producto sanitario funciona con una APP solo en teléfonos Android. Los resultados testeados son 96% de sensibilidad y 94% de especificidad.